NICE recommends innovative psoriasis treatment secukinumab, with three month window for NHS implementation

By on Invalid date

The National Institute for Health and Care Excellence (NICE) has issued technology appraisal guidance for CosentyxTM (secukinumab). Secukinumab is an innovative new treatment licensed for use in adults with moderate-to-severe plaque psoriasis who are candidates for systemic* therapy.¹

The announcement by NICE means that its guidance is now final.² Secukinumab is recommended as an option for adults with severe plaque psoriasis who have failed to respond to, are contraindicated to or cannot take standard systemic therapies.²† The NHS now has a three month deadline to ensure it is made available to these patients.

Approximately two thirds of patients with moderate-to-severe psoriasis are failing to achieve a reduction of 75% in their psoriasis (current treatment goal) with currently available therapies.³

By 22 October 2015, secukinumab, which has consistently demonstrated high levels of skin clearance in clinical trials, should be available to eligible patients within the NHS.^4-8

How we reviewed this article:

Medical News Today has strict sourcing guidelines and draws only from peer-reviewed studies, academic research institutions, and medical journals and associations. We avoid using tertiary references. We link primary sources — including studies, scientific references, and statistics — within each article and also list them in the resources section at the bottom of our articles. You can learn more about how we ensure our content is accurate and current by reading our editorial policy.

1. Cosentyx - Summary of Product Characteristics (SmPC). 1-13 (2015).
2. National Institute for Health and Care Excellence technology appraisal guidance 350 - Secukinumab for treating moderate to severe plaque psoriasis.
3. Bewley, A., Bishop-Bailey, A., Hatchard, C. & Coope, H. PICTURE study : A real world study to assess the effectiveness of psoriasis management with biologic therapies in the UK. 23rd Eur. Acad. Dermatology Venereol. Congr. (2014).
4. Langley, R. G. et al. Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials. N. Engl. J. Med. 371, 326–38 (2014).
5. Blauvelt, A. et al. Secukinumab administration by pre-filled syringe: Efficacy, safety, and usability results from a randomized controlled trial in psoriasis (FEATURE). Br. J. Dermatol. (2014).
6. Paul, C. et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J. Eur. Acad. Dermatol. Venereol. 1–9 (2014).
7. Blauvelt, A. et al. Secukinumab Treatment Maintains Efficacy in Moderate to Severe Plaque Psoriasis Through Second Year of Treatment: A Randomized Extension of the ERASURE and FIXTURE Studies. In Abstracts at the American Academy of Dermatology Annual Meeting 2015 (2015).
8. Thaci, D. et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: 16-week results from CLEAR study. in Abstracts at the American Academy of Dermatology, Congree, San Francisco, USA (2015).
*Systemic: treatments or medication that travel through the blood stream, allowing them to be carried where they are needed to work.
† TA 350: Secukinumab is recommended, within its marketing authorisation, as an option for treating adults with plaque psoriasis only when: The disease is severe, as defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10; the disease has failed to respond to standard systemic therapies, for example, ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or these treatments are contraindicated or the person cannot tolerate them; the company provides secukinumab with the discount agreed in the patient access scheme.
▼ New medicines and vaccines are subject to additional monitoring by the European Medicines Agency. They must display an inverted black triangle in their package leaflets and summary of product characteristics, to encourage reporting of any suspected adverse reactions, it does not mean the medicine is unsafe.
Source:
http://www.novartis.co.uk/

Share this article

NICE recommends innovative psoriasis treatment secukinumab, with three month window for NHS implementation

How we reviewed this article:

Latest news